Recombinant Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (ab198288)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR16813] to Apolipoprotein CI/Apo-CI
- Suitable for: WB, IHC-P, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813]
See all Apolipoprotein CI/Apo-CI primary antibodies -
Description
Rabbit monoclonal [EPR16813] to Apolipoprotein CI/Apo-CI -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, IPmore details
Unsuitable for: Flow Cyt (Intra) or ICC/IF -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human fetal liver and Human plasma lysate. IHC-P: Human liver tissue. ICC/IF: HepG2 cells. Flow Cyt (intra): HeLa cells. IP: Human plasma whole cell extract .
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR16813 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab198288 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Detects a band of approximately 6.6 kDa (predicted molecular weight: 9 kDa).
|
|
IHC-P |
1/800. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
|
IP |
1/40.
|
Notes |
---|
WB
1/1000. Detects a band of approximately 6.6 kDa (predicted molecular weight: 9 kDa). |
IHC-P
1/800. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
IP
1/40. |
Target
-
Function
Appears to modulate the interaction of APOE with beta-migrating VLDL and inhibit binding of beta-VLDL to the LDL receptor-related protein. Binds free fatty acids and reduces their intracellular esterification. -
Tissue specificity
Synthesized mainly in liver and to a minor degree in intestine. Secreted in plasma. -
Sequence similarities
Belongs to the apolipoprotein C1 family. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 341 Human
- Omim: 107710 Human
- SwissProt: P02654 Human
- Unigene: 110675 Human
-
Alternative names
- APO C1 antibody
- Apo CI antibody
- Apo-CIB antibody
see all
Images
-
All lanes : Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (ab198288) at 1/1000 dilution
Lanes 1 & 3 : Untreated HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate
Lane 2 : HepG2 (Human hepatocellular carcinoma epithelial cell) treated with 300ng/ml BFA for 48 hours whole cell lysate
Lane 4 : HepG2 (Human hepatocellular carcinoma epithelial cell) treated with 300ng/ml BFA for 24 hours whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 9 kDa
Observed band size: 88 kDa why is the actual band size different from the predicted?
Exposure time: 180 secondsBlocking/dilution buffer: 5% NFDM/TBST.
We suggest treating cells with BFA which inhibits protein secretion.
-
Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (ab198288) at 1/1000 dilution + Human fetal liver lysate at 20 µg
Secondary
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 9 kDa
Observed band size: 6.6 kDa why is the actual band size different from the predicted?Blocking/dilution buffer: 5% NFDM/TBST.
-
Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (ab198288) at 1/5000 dilution + Human plasma lysate at 20 µg
Secondary
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 9 kDa
Observed band size: 6.6 kDa why is the actual band size different from the predicted?Blocking/dilution buffer: 5% NFDM/TBST.
-
Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling Apolipoprotein CI/Apo-CI with ab198288 at 1/1600 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Cytoplasm staining on Human liver tissue is observed. Counter stained with Hematoxylin.
Negative control: Used PBS instead of primary ab.Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunoprecipitation analysis of Human plasma whole cell extract labeling Apolipoprotein CI/Apo-CI using ab198288 at 1/40 dilution (Lane 2).
Lane 3: IP using Rabbit monoclonal IgG (ab172730) instead of ab198288 in Human plasma whole cell extract.
Lane 1: Input: 10 μg Human plasma whole cell extract.
Subsequent WB detection was performed using ab198288 at 1/1000 dilution.
An Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1500 was used as secondary antibody.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (9)
ab198288 has been referenced in 9 publications.
- Lu C et al. Construction of a novel mRNA-miRNA-lncRNA network and identification of potential regulatory axis associated with prognosis in colorectal cancer liver metastases. Aging (Albany NY) 13:14968-14988 (2021). PubMed: 34081622
- Miller AL et al. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers (Basel) 13:N/A (2021). PubMed: 34298684
- Cui Y et al. Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma. Front Oncol 10:1436 (2020). PubMed: 32974161
- Ren H et al. Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer. Cancer Manag Res 11:4917-4930 (2019). PubMed: 31213910
- Yi J et al. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer. Ann Transl Med 7:380 (2019). PubMed: 31555694
- Zhang H et al. Characterization of apolipoprotein C1 in hepatitis C virus infection and morphogenesis. Virology 524:1-9 (2018). PubMed: 30130702
- Kim WS et al. Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia. Front Neurosci 12:847 (2018). PubMed: 30487733
- Andreo U et al. Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimericfah-/-Mice. Cell Mol Gastroenterol Hepatol 4:405-417 (2017). PubMed: 28936471
- Yang Q et al. iTRAQ-Based Proteomics Investigation of Aqueous Humor from Patients with Coats' Disease. PLoS One 11:e0158611 (2016). WB . PubMed: 27416065